Gian Marco Elisi / Ricercatore Legge 240/10 a tempo determinato

Dr. Gian Marco Elisi is currently a post-doctoral researcher (RTD-A) in the Computer-Assisted Molecular Design laboratory of the Deparment of Biomolecular Sciences of the University of Urbino. His research activies revoleve around computational medicinal chemistry, in particular free-energy simulations for perspective drug design and the application of virtual screening protocols applied to ultra-large libraries. He is coauthor of 10 scientific articles, mainly focusing on melatonin receptors and melatonergic ligands. His doctoral studies were supervised by Prof. Silvia Rivara at the Food and Drug Department of the University of Parma. He graduated in Industrial Pharmacy (CTF) with 110/110 at the University of Modena and Reggio Emilia. During his PhD secondment, he spent a period abroad at the University of Geneva. Additionaly, he took the position of Senior Scientist at the Molecular Architects department of Evotec in Verona in 2023, before joining the University of Urbino as junior faculty member.

Bedini A, Elisi GM, Fanini F, Retini M, Scalvini L, Pasquini S, Contri C, Varani K, Spadoni G, Mor M, Vincenzi F, Rivara S. “Binding and unbinding of potent melatonin receptor ligands: mechanistic simulations and experimental evidence”. J. Pineal Res., 2024, 76, 2, e12941.

Caputo A, Sartini S, Levati E, Minato I, Elisi GM, Di Stasi A, Guillou C, Goekjian PG, Garcia P, Gueyrard D, Bach S, Comte A, Ottonello S, Rivara S, Montanini B. “An optimized pipeline for the discovery of new antimicrobial compounds targeting bacterial RNA polymerase complex formation”. Antibiotics, 2022, 11, 10, 1449.

Mari M, Elisi GM, Bedini A, Lucarini S, Retini M, Lucini V, Scaglione F, Vincenzi F, Varani K, Castelli R, Mor M, Rivara S, Spadoni G. “Melatonin analogues probing the 2-phenyl-binding pocket reveal tolerance to hydrophilic groups”. Eur J Med Chem, 2022, 243, 14762.

Elisi GM, Scalvini L, Lodola A, Bedini A, Spadoni G, Rivara S. “In silico drug discovery of melatonin receptor ligands with therapeutic potential”. Expert Opin Drug Discov., 2022, 17, 4, 343-54.

Lauriola A, Uliassi E, Santucci M, Bolognesi ML, Mor M, Scalvini L, Elisi GM, Gozzi G, Tagliazucchi L, Marverti G, Ferrari S, Losi L, D’Arca D, Costi MP. “Identification of a quinone derivative as YAP/TEAD activity modulator from a repurposing library”. Pharmaceutics 2022, 14, 2, 391.

Elisi GM, Scalvini L, Lodola A, Mor M, Rivara S. “Free-energy simulations support a lipophilic binding route for melatonin receptors”. J Chem Inf Model. 2022, 62, 1, 210-22.

Ferlenghi F, Mari M, Gobbi G, Elisi GM, Mor M, Rivara S, Vacondio F, Bartolucci S, Bedini A, Fanini F, Spadoni G, “N-(anilinoethyl)amide melatonergic ligands with improved water solubility and metabolic stability” ChemMedChem. 2021, 16, 19, 3071.

Elisi GM, Bedini A, Scalvini L, Carmi C, Bartolucci S, Lucini V, Scaglione F, Mor M, Rivara S, Spadoni G, “Chiral recognition of flexible melatonin receptor ligands induced by conformational equilibria”, Molecules 2020, 4, 25, 4057.

Pala D, Scalvini L, Elisi GM, Lodola A, Mor M, Spadoni G, Ferrara FF, Pavoni E, Roscilli G, Milazzo FM, Battistuzzi G, Rivara S, Giannini G, “New classes of potent heparanase inhibitors from ligand-based virtual screening”, J Enzyme Inhib Med Chem 2020, 35, 1, 1685-96.

Elisi GM, Santucci M, D'Arca D, Lauriola A, Marverti G, Losi L, Scalvini L, Bolognesi ML, Mor M, Costi MP, “Repurposing of drugs targeting YAP-TEAD functions”, Cancers, 2018, 10, 9, 329.